STONY BROOK – Molecular tagging technologies specialist Applied DNA Sciences (ADNAS) has signed a non-binding Memorandum of Understanding (MoU) with the Indian conglomerate Reliance Industries Ltd (RIL), through which the pair will develop and commercialise a recycled polyester fabric authenticated throughout its lifecycle by ADNAS’ CertainT solution.

RIL’s R|Elan GreenGold fibre, used by the likes of Lee, Wrangler and Kappa, is produced entirely from recycled PET bottles and, according to the firm, has one of the industry’s lowest fibre carbon footprints. With this in mind, the authentication Applied DNA’s solution can provide will ensure customers that the product they buy is indeed sustainably produced and is not the subject of false claims or even counterfeit.

By Billy Hunter | 10 December 2019

Applied DNA Sciences, Inc. (Applied DNA), a leader in large-scale PCR-based DNA manufacturing and authentication, announced today that it has signed a non-binding memorandum of understanding (MOU) with Reliance Industries Ltd. (RIL) to develop and commercialize apparel made from RIL’s R|Elan GreenGold fabric and Recron GreenGold recycled polyester fibre and filament powered by CertainT.

The collaboration as set forth in the MOU, provides for potentially extending apparel manufacturing using R|Elan GreenGold, and the use of recycled polyester through Recron GreenGold into consumer and industrial applications in the global markets. Applied DNA says it has already demonstrated with its supply chain partners, full end- to-end traceability by tagging over 20 million pounds of recycled polyester, testing of hundreds of samples, and tracking of forensically authenticated products from fibre to finished goods. Commercial products are sold in over 4000 US retail stores, with expansion into international markets before the end of 2019.

Applied DNA Sciences, a leader in large-scale PCR-based DNA manufacturing and authentication, has signed a non-binding memorandum of understanding (MOU) with Reliance Industries Ltd (RIL) to develop and commercialise apparel made from RIL’s R|Elan GreenGold fabric and Recron GreenGold recycled polyester fibre and filament powered by CertainT.

The collaboration as set forth in the MOU, provides for potentially extending apparel manufacturing using R|Elan GreenGold, and use of recycled polyester through Recron GreenGold into consumer and industrial applications in the global markets.

Applied DNA has already demonstrated with its supply chain partners, full end-to-end traceability by tagging over 20 million lbs of recycled polyester, testing of hundreds of samples, and tracking of forensically authenticated products from fibre to finished goods. Commercial products are sold in over 4,000 US retail stores, with expansion into international markets before the end of 2019.

CertainT® Platform Protects IP and Proves Product Origins

STONY BROOK, N.Y., December 11, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions and nucleic acid-based biotherapeutic development, announced today it will conduct a funded pre-commercial pilot to tag cannabidiol (CBD) oil for Old Port Oil, Company (“Old Port Oil”) using its CertainT^® platform to tag, test and track the CBD oil product. Newly formed Old Port Oil, a cannabis processor company, will soon launch its first CBD product and turned to Applied DNA’s CertainT platform to ensure its brand and IP protection and prove the origin of its CBD product proudly produced in Maine. Upon successful completion of the pilot project, Old Port Oil expects to ramp up commercial production in January and anticipates it will tag 100% of its inaugural product over the course of 2020.

Scott Keeler, Founder Old Port Oil, stated, “We are very impressed with the CertainT platform which allows us to provide our customers with uncontestable proof of product origin and, at the same time, protects our brand from counterfeits and misuse in the market place.”

John Shearman, Vice President of Marketing and Cannabis Business Lead at Applied DNA, said, “We are very excited to have the opportunity to work with Scott and the team at Old Port Oil to implement our CertainT platform as a strategic component to their business plan and go-to-market strategy. As the cannabis industry continues to mature and go through growing pains just like any other emerging industry, it will require an ecosystem of technologies, processes and procedures and compliance frameworks to remove the uncertainty over time. Companies like Old Port Oil, who recognize this need out-of-the-gate and implement innovative solutions, will lead the market and create successful companies.”

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

About Old Port Oil
Old Port Oil Co is a wholesale CBD oil manufacturer and processor based in Maine. We locally source our products from tested and certified ingredients and use state-of-the-art equipment and techniques to produce oils, blends, and isolates of the highest quality.  We are proud to be the first company in the country to utilize CertainT technology to produce the industry’s first molecular tagged and traceable CBD products that allows us to track product from seed to store.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to substantial doubt relating to Applied DNA’s ability to continue as a going concern, the possibility of failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its history of net losses, limited financial resources, limited market acceptance, its ability to penetrate key markets, including its ability to successfully enter into commercial contracts for the implementation of its CertainT® platform, shifting enforcement priorities of US federal laws relating to cannabis, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

By Arthur Friedman, December 10, 2019

Applied DNA Sciences Inc. has signed a non-binding memorandum of understanding (MOU) with Reliance Industries Ltd. (RIL) to develop and commercialize apparel made from Reliance’s R|Elan GreenGold fabric and Recron GreenGold recycled polyester fiber and filament powered by CertainT.

MOU lays the groundwork for potential commercial implementation

STONY BROOK, N.Y., December 10, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing and authentication, announced today that it has signed a non-binding memorandum of understanding (the “MOU”) with Reliance Industries Ltd. (“RIL”) to develop and commercialize apparel made from RIL’s R|Elan GreenGold® fabric and Recron GreenGold® recycled polyester fiber and filament powered by CertainT. The collaboration as set forth in the MOU, provides for potentially extending apparel manufacturing using  R|Elan GreenGold®, and the use of recycled polyester through Recron GreenGold into consumer and industrial applications in the global markets. Applied DNA has already demonstrated with its supply chain partners, full end-to-end traceability by tagging over 20 million lbs of recycled polyester, testing of hundreds of samples, and tracking of forensically authenticated products from fiber to finished goods. Commercial products are sold in over 4,000 US retail stores, with expansion into international markets before the end of 2019.

Prior to the signing of the MOU, Applied DNA and RIL had tagged recycled polyester at RIL’s facilities in India in successful proof-of-concept studies. Under the MOU, samples will be tested both on-site and at Applied DNA’s laboratory in Ahmedabad. The groundwork for commercial scale-up for DNA production for manufacture of CertainT tagged staple fiber and filament yarn is underway.  Joint marketing will support sales and business development in US and European markets.

“At Reliance, we believe that sustainability with traceability is a must and not a maybe. We aim to be an industry leader in sustainability for recycled polyester, and that is why we believe CertainT is the best solution,” stated Hemant Sharma, Head Polyester Business, RIL.

As there is much uncertainty related to the use of post-consumer recycled polyester to make sustainability product claims, brands and retailers can be confident that their products marketed and sold as 100% recycled are proven with forensic assurance and authentication.

“Our R|Elan brand is growing in apparel and it is used by brands such as Arrow, Lee, Wrangler, Raymond, Anita Dongre, Kappa and many more. These brands now have the option to add CertainT forensic traceability to assure that their products are sustainable, traceable and authentic,” stated Gunjan Sharma, Chief Marketing Officer – Polyester Business, RIL.

“Eco-friendly,” “natural,” “green,” and “organic” are typical sustainable claims and labels that can be confusing and misleading to consumers. Whilst more companies and key opinion leaders are espousing to be “green” through advertising and marketing, how do we know for sure that they are actually implementing business practices that minimize environmental impact?

“Without Applied DNA’s proprietary molecular tagging system, the uncertainty, and risk is too high and the burden of proof is much harder for brands and retailers. So we are very excited to bring a solution that we believe can truly make a difference for the planet, the people and our processes,” added Gunjan Sharma.

RIL’s Recron GreenGold fiber is made from 100% used PET bottles. It has one of the lowest fiber carbon footprints globally. Sustainable feedstock developments include modern in-house manufacturing for recycling waste PET bottles into sustainable fashion solutions. Eco-friendly manufacturing to ensure maximum water is recycled (up to 90%) and all water re-used in manufacturing and horticulture. Reliance operates a state-of-the-art water effluent treatment process system consistent with their zero waste concept that all material is either used in process or sold in market.

“Reliance is a key partner for us because you can trust that the post-consumer recycled polyester process is meticulously managed from bottle to fiber, and that scalability is done in a fully controlled environment. Secure chain of custody is a true value addition to the supply chain, and CertainT tagged recycled polyester provides an indelible stamp of approval that many brands and manufacturers need,” stated Dr. James A. Hayward, President and CEO, Applied DNA Sciences.

About Reliance Industries Limited
Reliance Industries Limited (RIL) is India’s largest private sector company, with a consolidated turnover of INR 622,809 crore ($90.1 billion), cash profit of INR 64,478 crore ($ 9.3 billion), and net profit of INR 39,588 crore ($5.7 billion) for the year ended March 31, 2019. RIL’s activities span hydrocarbon exploration and production, petroleum refining and marketing, petrochemicals, retail and digital services.

RIL is the top most ranked company from India to feature in Fortune’s Global 500 list of ‘World’s Largest Corporations’ – currently ranking 106th in terms of both revenues and profits. The company stands 71st in the ‘Forbes Global 2000’ rankings for 2019 – top-most among Indian companies. It ranks 10th among LinkedIn’s ‘The Best Companies to Work For In India’ (2019).

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to substantial doubt relating to Applied DNA’s ability to continue as a going concern, the possibility of failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, its history of net losses, limited financial resources, limited market acceptance, its ability to penetrate key markets, including its ability to successfully enter into commercial contracts for the implementation of its CertainT® platform and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

INVESTOR CONTACT: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
APPLIED DNA PROGRAM CONTACT, MeiLin Wan, Applied DNA Sciences, 631 240 8800, textilesales@adnas.com
RIL PROGRAM CONTACT: Tushar Pania, Reliance Industries, +91 22 35557918; +91 9820088536

 

STONY BROOK, N.Y., December 5, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release financial results for its fiscal 2019 fourth quarter ended September 30, 2019 after market close on Thursday, December 12, 2019. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Time that will also be broadcast live over the Internet.

What: Applied DNA’s Fiscal 2019 Fourth Quarter Financial Results Conference Call

When: Thursday, December 12, 2019, at 4:30 p.m. Eastern Time

Where: Via phone by dialing +1 844-887-9402 or +1 412-317-6798 and ask to join the Applied DNA call; via webcast.

A telephonic replay of the conference call will be available for one day and may be accessed by calling +1 877-344-7529 or +1 412-317-0088 with the passcode 10136194. The webcast will be archived within the ‘Events and Presentations’ portion of the ‘Investors’ page to the company’s website.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping, and pre-clinical nucleic acid-based therapeutic drug candidates.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to the substantial doubt relating to Applied DNA’s ability to continue as a going concern, our ability to successfully enter into commercial contracts for the implementation of our CertainT® platform, the possibility of failure to make timely payment on its outstanding secured convertible notes and resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA’s assets, the Company’s history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018, as amended, and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

INVESTOR CONTACT: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com

Applied DNA Sciences announced that LineaRx, the Company’s majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has signed a definitive agreement with Tyme Technologies, to supply the Company’s Vita-Assay™ invasive Circulating Tumor Cell (iCTC) capture assay and associated services for use in the pivotal stage of the TYME-88-PANC clinical trial for patients with third-line pancreatic cancer (the “Agreement”).

Under the terms of the Agreement, TYME has the option to purchase from the Company up to 3,000 Vita-Assay kits and associated iCTC analytical and storage services over the course of treatment of up to 250 patients. The potential value of the Agreement is the largest contract to-date for LineaRx, and the largest in the development history of the iCTC assay.

The Company and TYME have previously announced a study demonstrating correlation between the number of iCTCs in a patient’s blood and their disease status, as observed in TYME’s SM-88 Phase II trial for recurrent prostate cancer. The study demonstrated that SM-88 had very encouraging efficacy and safety outcomes for prostate cancer patients where sparing testosterone was important. The study also showed that reduction of CTCs, an important prognostic indicator, may prove to be a better surrogate for patient outcomes than PSA, particularly for SM-88 and other non-hormonal agents.

DNA tags added to excipients during the manufacture of tablets remain stable and can be used for authentication – even after months of challenging environmental conditions.

The study conducted by scientists at King’s College London in collaboration with Dubai Police and Applied DNA Sciences – which supplied the tags – is thought to be the first to assess adding DNA markers directly into a powder excipient mix.

The researchers used standard pharmaceutical processing equipment to manufacture the 400mg lactose tablets, and found that the physical properties of the resulting pills – such as their hardness, uniformity and tendency to chip or crumble on compression – was unaffected by the DNA tags.